NCT04511416View on ClinicalTrials.gov

Preventing Cognitive Decline with Metformin

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cognitive Decline
Interventions
DRUG

Metformin XR, 500-2000mg nocte

Metformin XR, 500-2000mg nocte

Trial Locations (1)

2010

Garvan Institute of Medical Research, Sydney

Sponsors
All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

Garvan Institute of Medical Research

OTHER